PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Drug Residues Release Newly Improved Multi-Sulphonamide Testing Platform - Randox Drug Residues have released their newly improved Antimicrobial Array I. This comprehensive multiplex testing platform allows for the simultaneous detection of 15 of the most commonly abused sulphonamides in food production and agricultural
Randox Drug Residues Release Newly Improved Multi-Sulphonamide Testing Platform

 

NewswireToday - /newswire/ - Crumlin, Antrim, United Kingdom, 2011/06/23 - Randox Drug Residues have released their newly improved Antimicrobial Array I. This comprehensive multiplex testing platform allows for the simultaneous detection of 15 of the most commonly abused sulphonamides in food production and agricultural.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Excellent limits of detection and simple sample preparations combine to make this product an impressive multi-analyte testing platform. Limits of detection for milk range from 0.5-2.5ppb which surpass any tolerance or maximum residue limits in place from regulatory bodies. Sample preparations are also available for honey, tissue, urine and feed, resulting in valuable time savings. Utilising the revolutionary Biochip Array Technology developed by Randox, high quality and reliable results are guaranteed.

This new testing platform includes the following compounds: Sulphamerazine, Sulphadoxine, Sulphapyridine, Sulphamethoxypyridazine, Sulphachlorpyridazine, Sulphathiazole, Sulphisoxazole, Sulphadimethoxine, Sulphaquinoxaline, Sulphamethazine, Sulphadiazine, Sulphamethizole, Sulphamethoxazole, Sulphamonomethoxine and Trimethoprim. Testing all of these compounds simultaneously offers a more complete and reliable detection method.

The Antimicrobial Array I is used in conjunction with the patented Evidence Investigator system which allows for cost effective high throughput screening for a range of drug residues. The Evidence Investigator is a semi-automated biochip analyser

About Randox Drug Residues

Randox Drug Residues (drug-residues.com) is dedicated to the development and manufacture of high quality drug residue testing solutions. We use in house developed antibodies and conjugates for a wide range of our screening products including the patented Biochip Array Technology – a proven multiplexing platform. We provide a range of excellent tools for screening for antimicrobials, growth promoting hormones and drugs of abuse in animals and foodstuffs. We offer excellent limit of detections and simple sample preparations. Our portfolio includes 25 ELISA’s and 5 multiplex screening platforms. All products are manufactured at our state-of-the-art ISO 13485 accredited manufacturing plant in the UK.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Randox Drug Residues Release Newly Improved Multi-Sulphonamide Testing Platform

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)